Snehal Gaikwad

Dr. Snehal Gaikwad

Laboratory of Cancer Biology and Genetics, Centre of Cancer Research, National Cancer Institute,National Institutes of Health, Bethesda, MD,USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DCDavid R. Calabrese
David R. Calabrese
XCXiang Chen
Xiang Chen
ELElena C. Leon
Elena C. Leon
SGSnehal Gaikwad
Snehal Gaikwad
Zaw PhyoZaw Phyo
Zaw Phyo
JJJohn S. Schneekloth, Jr
John S. Schneekloth, Jr
G-quadruplexes (G4s) are noncanonical DNA structures that frequently occur in the promoter regions of oncogenes, such as MYC, and regulate gene expression. Although G4s are attractive therapeutic targets, ligands capable of discriminating between different G4 structures are rare. Here, we describe DC-34, a small molecule that potently downregulates MYC transcription in cancer cells by a G4-dependent mechanism. Inhibition by DC-34 is significantly greater for MYC than other G4-driven genes. We use chemical, biophysical, biological, and structural studies to demonstrate a molecular rationale for the recognition of the MYC G4. We solve the structure of the MYC G4 in complex with DC-34 by NMR spectroscopy and illustrate specific contacts responsible for affinity and selectivity. Modification of DC-34 reveals features required for G4 affinity, biological activity, and validates the derived NMR structure. This work advances the design of quadruplex-interacting small molecules to control gene expression in therapeutic areas such as cancer.

13 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SGSnehal Gaikwad
Snehal Gaikwad
Zaw PhyoZaw Phyo
Zaw Phyo
AAAnaisa Quintanilla Arteaga
Anaisa Quintanilla Arteaga
SGSayeh Gorjifard
Sayeh Gorjifard
DCDavid R. Calabrese
David R. Calabrese
BMBeverly Mock
Beverly Mock
New approaches to target MYC include the stabilization of a guanine-rich, G-quadruplex (G4) tertiary DNA structure in the NHE III region of its promoter. Recent screening of a small molecule microarray platform identified a benzofuran, D089, that can stabilize the MYC G4 and inhibit its transcription. D089 induced both dose- and time-dependent multiple myeloma cell death mediated by endoplasmic reticulum induced stress. Unexpectedly, we uncovered two mechanisms of cell death: cellular senescence, as evidenced by increased levels of p16, p21 and γ-H2AX proteins and a caspase 3-independent mechanism consistent with pyroptosis. Cells treated with D089 exhibited high levels of the cleaved form of initiator caspase 8; but failed to show cleavage of executioner caspase 3, a classical apoptotic marker. Cotreatment with the a pan-caspase inhibitor Q-VD-OPh did not affect the cytotoxic effect of D089. In contrast, cleaved caspase 1, an inflammatory caspase downstream of caspases 8/9, was increased by D089 treatment. Cells treated with D089 in addition to either a caspase 1 inhibitor or siRNA-caspase 1 showed increased IC50 values, indicating a contribution of cleaved caspase 1 to cell death. Downstream effects of caspase 1 activation after drug treatment included increases in IL1B, gasdermin D cleavage, and HMGB1 translocation from the nucleus to the cytoplasm. Drug treated cells underwent a ‘ballooning’ morphology characteristic of pyroptosis, rather than ‘blebbing’ typically associated with apoptosis. ASC specks colocalized with NLRP3 in proximity ligation assays after drug treatment, indicating inflammasome activation and further confirming pyroptosis as a contributor to cell death. Thus, the small molecule MYC G4 stabilizer, D089, provides a new tool compound for studying pyroptosis. These studies suggest that inducing both tumor senescence and pyroptosis may have therapeutic potential for cancer treatment.

1 September 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JSJohn K. Simmons
John K. Simmons
AMAleksandra M Michalowski
Aleksandra M Michalowski
BGBenjamin J. Gamache
Benjamin J. Gamache
WDWendy DuBois
Wendy DuBois
JPJyoti Patel
Jyoti Patel
BMBeverly Mock
Beverly Mock
Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 human cancer cell lines responded synergistically (CI<1) when treated with this drug combination compared with single agents. In addition, a breast cancer patient–derived xenograft, and a BCL-XL plasmacytoma mouse model both showed enhanced responses to the combination compared with single agents. Mice bearing plasma cell tumors lived an average of 70 days longer on combination treatment compared with single agents. A set of 37 genes cooperatively affected (34 downregulated; 3 upregulated) by the combination responded pharmacodynamically in human myeloma cell lines, xenografts, and a P493 model, and were both enriched in tumors, and correlated with prognostic markers in myeloma patient datasets. Genes downregulated by the combination were overexpressed in several untreated cancers (breast, lung, colon, sarcoma, head and neck, myeloma) compared with normal tissues. The MYC/E2F axis, identified by upstream regulator analyses and validated by immunoblots, was significantly inhibited by the drug combination in several myeloma cell lines. Furthermore, 88% of the 34 genes downregulated have MYC-binding sites in their promoters, and the drug combination cooperatively reduced MYC half-life by 55% and increased degradation. Cells with MYC mutations were refractory to the combination. Thus, integrative approaches to understand drug synergy identified a clinically actionable strategy to inhibit MYC/E2F activity and tumor cell growth in vivo. Mol Cancer Ther; 16(9); 2008–21. ©2017 AACR.

15 October 2012
Verified
Journal Article
Closed access
SGSnehal Gaikwad
Snehal Gaikwad
PRPritha Ray
Pritha Ray

3 April 2023
Verified
Other
Open access
JGJoy M. Gary
Joy M. Gary
JSJohn K. Simmons
John K. Simmons
JXJinfei Xu
Jinfei Xu
SZShuling Zhang
Shuling Zhang
TPTyler J. Peat
Tyler J. Peat
BMBeverly Mock
Beverly Mock
Supplemental Figures S1-S4 + two supp. tables